HMGB1-mediated restriction of EPO signaling contributes to anemia of inflammation
Dulmovits BM, Tang Y, Papoin J, He M, Li J, Yang H, Addorisio ME, Kennedy L, Khan M, Brindley E, Ashley RJ, Ackert-Bicknell C, Hale J, Kurita R, Nakamura Y, Diamond B, Barnes BJ, Hermine O, Gallagher PG, Steiner LA, Lipton JM, Taylor N, Mohandas N, Andersson U, Al-Abed Y, Tracey KJ, Blanc L. HMGB1-mediated restriction of EPO signaling contributes to anemia of inflammation. Blood 2022, 139: 3181-3193. PMID: 35040907, PMCID: PMC9136881, DOI: 10.1182/blood.2021012048.Peer-Reviewed Original ResearchConceptsAnemia of inflammationDamage-associated molecular pattern moleculesHigh-mobility group box 1 proteinMobility group box 1 proteinErythroid precursorsGroup box 1 proteinAdvanced glycation end productsAnti-HMGB1 antibodyGlycation end productsMolecular pattern moleculesChronic phaseSepsis onsetChronic diseasesHMGB1 receptorsAnemia developmentPattern moleculesAnemiaGenetic ablationInflammationMurine precursorRefractory stateHMGB1Reduced expansionEPO signalingDeleterious effects